ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC

Results from a phase II study of bevacizumab and erlotinib in people with advanced hereditary leiomyomatosis and papillary renal cell cancer (HLRCC) or sporadic papillary RCC were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. This study included 83 patients with papillary RCC. Half of the patients […]

read more

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary condition associated with multiple smooth muscle tumours (leiomyomas) in the skin, uterine fibroids (non-cancerous growths in a woman’s uterus), and renal cell carcinoma (RCC). A recent study published in European Urology Oncology looks at the clinical features, molecular genetics and prognosis in 69 families with HLRCC. In […]

read more

An overview of the management of rare subtypes of kidney cancer

This interview with Dr Ramaprasad Srinivasan from the National Cancer Institute in Bethesda, USA, discusses the management of sarcomatoid renal cell carcinoma (RCC), papillary RCC, and hereditary RCC, such as hereditary leiomyomatosis RCC (HLRCC). Watch the interview with Dr Srinivasan on Practice Update here

read more

Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer

In this video, Dr W. Marston Linehan, chief of the Urologic Oncology Branch of the National Cancer Institute in America, discusses the treatment of hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is very rare inherited condition, in which patients are at risk of developing non-cancerous (benign) tumours in the muscle under the skin (cutaneous leiomyomas), […]

read more
Showing all 4 results